

SHL/SEC/2022

January 31, 2022

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Company Code: 537253

Dear Sir,

Sub. : Outcome of the 247th Board Meeting held on 31.01.2022.

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Monday, January 31, 2022, the meeting was started at 03:30p.m., and concluded at 4:30 p.m.

1. **Approved Unaudited Financial Results (Standalone & consolidated) for the 03rd quarter/nine months ended December 31, 2021 of the Financial Year 2021-22 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).**
2. Noted sanction of GECL 1.0 ext. scheme by State Bank of India vide Sanction letter no. RM-SME/2021-22 dated 26.11.202.
3. (a)Noted modification of Charge ID100112043 due to sanction of WCTL under GECL 1.0Ext.
(b) Satisfaction of Charge ID 100104872, Charge ID 100104927, Charge ID 100104936 and Charge ID 100104948 in favour of Kotak Mahindra Bank due to repayment of vehicle loan.
(c) Satisfaction of Charge ID 100032940 w.e.f. 06.12.2021 in favour of Tata Financial Services Ltd. due to repayment of loan.
4. Recommended Re-appointment of Mr. Anil Kumar Khaitan (DIN: 00759951) as Chairman & Managing Director of the Company.

Name of Director & DIN	Anil Kumar Khaitan (DIN: 00759951)
Reason for change	Re-appointment (subject to approval via Special Resolution by Shareholders in General Meeting/Annual General Meeting).
Date of Re-Appointment /Terms of Re-appointment	5 years from 01.04.2022 to 31.03.2027 Other terms and conditions as may be approved by the shareholders through special resolution.
Brief Profile	Mr. Anil Khaitan, Chairman SNK Corp., attended Vincent High School, Mussoorie and thereafter completed his B.Com Degree

1 | Page

		<p>and joined family business in 1976. He qualified his MBA from IMI, Geneva in the year 1981.</p> <p>Mr. Khaitan has diversified business experience of 44 years relating to Jute Industry, Paper Industry, Pharmaceutical Industry, Copper & Steel Industry, apart from our International Operations.</p> <p>Mr. Khaitan over the years has gained expertise in strategic business planning, financial management and effective development of Human Resource.</p> <p>Mr. Khaitan is past President of PHD CCI, member of Executive Committee, FICCI, member of Managing Committee, ASSOCHAM, Member of ICSI – ASB (Institute of Company Secretaries of India-Auditing Standards Board, Chairman – Grievance Redressal Committee, ICSI RVO, Independent Director of Governing Body, ICSI Registered Valuers Organisation.</p>
Disclosure Relationship Directors	of with	Mr. Anil Kumar Khaitan is Chairman & Managing Director and Promoter of the Company.

You are requested to take the above information in your record and oblige us.

Thanking you,
Yours sincerely,
for **Sunil Healthcare Limited**

Santosh Kumar Sharma
Company Secretary
FCS-6817
Date: 31.01.2022
Place: New Delhi
Encl.: a/a

**SUNIL HEALTHCARE LIMITED**

Registered Office

 38E/252-A, Vijay Tower, Shahpurjat, New Delhi-110049
 Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com
 CIN : L24302DL1973PLC189662
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2021

Rs. in Lakhs

		Standalone					Year Ended Standalone 31st March 2021	Consolidated					Year Ended Consolidated 31st March 2021
		Quarter ended		Nine Months Ended				Quarter ended		Nine Months Ended			
		31st December 2021	30th September 2021	31st December 2020	31st December 2021	31st December 2020	31st December 2021	30th September 2021	31st December 2020	31st December 2021	31st December 2020		
Particulars		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	3,115.40	2,806.43	2,330.81	8,539.82	6,698.23	8,963.11	3,147.46	2,918.67	2,250.98	8,716.91	6,699.42	9,029.19
2	Other Income	17.44	51.78	366.31	87.81	433.59	562.07	15.48	42.59	359.97	82.48	439.09	557.89
3	Total Income (1+2)	3,132.84	2,858.21	2,697.12	8,627.63	7,131.82	9,525.18	3,162.94	2,961.26	2,610.95	8,799.39	7,138.51	9,587.08
4	Expenses												
	a) Cost of Materials consumed	1,146.92	997.78	834.26	3,146.84	2,273.90	3,261.55	1,146.92	997.78	834.26	3,146.84	2,273.90	3,261.55
	b) Purchase of Stock-in-trade	27.86	-	0.48	27.86	0.48	-	27.86	-	0.48	27.86	0.48	-
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(16.08)	246.45	560.30	383.97	1,028.09	1,011.86	(26.42)	332.65	500.84	467.80	975.05	1,008.73
	d) Employees benefit expenses	364.68	337.79	316.98	1,052.20	937.65	1,229.52	364.68	337.79	316.98	1,052.20	937.65	1,229.52
	e) Finance Costs	74.17	91.06	102.39	271.69	393.21	530.85	74.17	91.06	102.39	271.69	393.21	530.85
	f) Depreciation and amortisation	161.06	157.59	154.91	473.99	460.59	611.30	161.10	157.63	154.92	474.11	460.63	611.35
	g) Other Expenses	1,063.20	969.10	716.86	2,864.52	2,018.16	2,845.16	1,110.49	1,020.26	703.73	2,998.85	2,102.40	3,000.40
	Total Expenses	2,821.81	2,799.77	2,686.18	8,221.07	7,112.08	9,490.24	2,858.80	2,937.17	2,613.60	8,439.35	7,143.32	9,642.40
5	Profit before tax (3-4)	311.03	58.44	10.94	406.56	19.74	34.94	304.14	24.09	(2.65)	360.04	(4.81)	(55.32)
6	Tax Expenses (Net)	87.27	18.79	(3.41)	115.65	(0.92)	7.41	87.96	20.12	(4.59)	119.05	(0.78)	8.47
	a) Current Tax												
	i)-Current Tax	50.75	(16.76)	-	67.34	-	-	51.43	(16.06)	(1.18)	69.37	0.14	0.23
	ii)-Tax for Earlier Period	-	-	4.64	-	4.64	4.64	0.01	0.63	4.64	1.37	4.64	5.47
	b) Deferred Tax Charged/(Credit)	36.52	35.55	(8.05)	48.31	(5.56)	2.77	36.52	35.55	(8.05)	48.31	(5.56)	2.77
7	Profit/(loss) after tax	223.76	39.65	14.35	290.91	20.66	27.53	216.18	3.97	1.94	240.99	(4.03)	(63.79)
8	Other Comprehensive Income (OCI)												
	a) Items that will not be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	1.98	0.52	2.00	(44.17)	(3.72)	(44.68)	1.98
	b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	-	-	-	-	-	-
9	Total Comprehensive Income	223.76	39.65	14.35	290.91	20.66	29.51	216.70	5.97	(42.23)	237.27	(48.71)	(88.08)
10	Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11	Other Equity						3,781.78						3,346.25
12	Earning per share of Rs.10/- each(not annualised)												
	(a) Basic (Rs.)	2.18	0.39	0.14	2.84	0.20	0.27	2.11	0.04	0.02	2.35	(0.04)	(0.62)
	(b) Diluted (Rs.)	2.18	0.39	0.14	2.84	0.20	0.27	2.11	0.04	0.02	2.35	(0.04)	(0.62)

Notes:-

- COVID - 19 pandemic has caused serious disruption on the global economic and business environment. There is an uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these Financial results on the carrying value of its assets and liabilities as on 31.12.2021. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of these assets and to discharge its obligation as adequate liquidity is available. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.
- As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on January 31, 2022.

Anil Khaitan

(Chairman cum Managing Director)

DIN 00759951

Place: NEW DELHI

Date: 31-01-2022

JKVS & CO.

Chartered Accountants

Review Report on unaudited standalone quarterly and nine months ended December 31, 2021 financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended

To the Board of Directors of Sunil Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarterly and nine months ended December 31, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi
Date: January 31, 2022



For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E

Sajal Goyal
Partner

Membership No. 523903
UDIN: 22523903AAAAAE2394

JKVS & CO.

Chartered Accountants

Independent Auditor's Review Report on consolidated unaudited quarterly and nine months financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarterly and nine months ended December 31, 2021, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities
 - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
 - b. Sunil Healthcare North America LLC (Incorporated in USA)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review according to the law of respective countries and whose financial results reflect total revenue from operation of Rs. 95.18 Lakhs and Rs. 358.72 Loss after tax of Rs. 4.25 Lakhs and Rs. 10.73 Lakhs and total comprehensive income of Rs. (3.72) Lakhs and Rs. (14.45) Lakhs for the quarter and nine months ended December 31, 2021 respectively. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: New Delhi
Date: January 31, 2022

For JKVS & Co.
Chartered Accountants
Firm Registration No. 318086E



Sajal Goyal
Sajal Goyal
Partner
Membership No. 523903
UDIN: 22523903AAAAAD3343